Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NGNE Stock Forecast 2025-2026
$14.73
Current Price
$210.08M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NGNE Price Targets
+388.8%
To High Target of $72.00
+212.3%
To Median Target of $46.00
+8.6%
To Low Target of $16.00
NGNE Price Momentum
-2.5%
1 Week Change
+33.9%
1 Month Change
-54.7%
1 Year Change
-35.6%
Year-to-Date Change
-80.2%
From 52W High of $74.49
+114.3%
From 52W Low of $6.88
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Neurogene (NGNE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NGNE and similar high-potential opportunities.
Latest NGNE Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, NGNE has a bullish consensus with a median price target of $46.00 (ranging from $16.00 to $72.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $14.73, the median forecast implies a 212.3% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mani Foroohar at Leerink Partners, projecting a 388.8% upside. Conversely, the most conservative target is provided by Keith Tapper at BMO Capital, suggesting a 8.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NGNE Analyst Ratings
7
Buy
0
Hold
0
Sell
NGNE Price Target Range
Low
$16.00
Average
$46.00
High
$72.00
Current: $14.73
Latest NGNE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NGNE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 14, 2025 | BMO Capital | Keith Tapper | Outperform | Maintains | $16.00 |
| Mar 25, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $50.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $55.00 |
| Nov 20, 2024 | BMO Capital | Keith Tapper | Outperform | Maintains | $45.00 |
| Nov 19, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $55.00 |
| Nov 12, 2024 | BMO Capital | Keith Tapper | Outperform | Maintains | $60.00 |
| Nov 12, 2024 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $72.00 |
| Nov 12, 2024 | Baird | Joel Beatty | Outperform | Maintains | $72.00 |
| Nov 12, 2024 | Stifel | Paul Matteis | Buy | Maintains | $60.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $55.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $49.00 |
| Jun 27, 2024 | BMO Capital | Keith Tapper | Outperform | Initiates | $65.00 |
| Jun 20, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $51.00 |
| Jun 11, 2024 | Baird | Joel Beatty | Outperform | Initiates | $54.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $51.00 |
| May 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $51.00 |
| May 8, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $55.00 |
| May 3, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $55.00 |
| Apr 29, 2024 | Leerink Partners | Mani Foroohar | Outperform | Initiates | $46.00 |
| Mar 21, 2024 | William Blair | Sami Corwin | Outperform | Initiates | $0.00 |
Neurogene Inc. (NGNE) Competitors
The following stocks are similar to Neurogene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neurogene Inc. (NGNE) Financial Data
Neurogene Inc. has a market capitalization of $210.08M with a P/E ratio of 0.0x. The company generates $925,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -8,930.3% and return on equity of -30.3%.
Valuation Metrics
Market Cap
$210.08M
Enterprise Value
$-76,033,512
P/E Ratio
0.0x
PEG Ratio
-3.2x
Price/Sales
227.1x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-8,930.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+142.1%
Current Ratio
20.8x
Debt/Equity
4.0x
ROE
-30.3%
ROA
-18.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Neurogene Inc. (NGNE) Business Model
About Neurogene Inc.
What They Do
Develops genetic medicines for neurological diseases.
Business Model
Neurogene Inc. operates by developing innovative gene therapies targeted at severe neurological disorders. The company generates revenue through partnerships, grants, and potential future sales of its therapies, focusing on rare conditions with significant unmet needs.
Additional Information
With a strong emphasis on using advanced genetic and cellular technologies, Neurogene's pipeline includes therapies for early-onset and hard-to-treat diseases. The company employs proprietary delivery systems to enhance treatment efficacy and safety, positioning itself within the growing personalized medicine landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
107
CEO
Dr. Rachel L. McMinn Ph.D.
Country
United States
IPO Year
2023
Website
www.neurogene.comNeurogene Inc. (NGNE) Latest News & Analysis
Latest News
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) reported Q1 2025 financial results, highlighting progress on its NGN-401 gene therapy for Rett syndrome and plans for a future registrational trial update.
Why It Matters
Neurogene's progress on NGN-401 for Rett syndrome signals potential value creation. Positive trial updates could influence stock performance and investor sentiment significantly.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) announced the approval of non-qualified stock options for 1,755 shares to a new employee, effective May 3, 2025, by its Compensation Committee.
Why It Matters
The grant of stock options to a new employee can indicate the company's growth potential and commitment to talent, potentially impacting stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) will present at the ASGCT 28th Annual Meeting on May 13-17, 2025, discussing gene therapy advancements and monitoring approaches for neurological diseases.
Why It Matters
Neurogene's participation in a major gene therapy conference highlights its advancements in genetic medicines, potentially boosting investor confidence and interest in its stock.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) announced a peer-reviewed publication showcasing its EXACT™ technology's effectiveness in regulating gene therapy for rare neurological diseases, including Rett syndrome.
Why It Matters
Neurogene's publication validates its EXACT™ technology, potentially enhancing gene therapy effectiveness for rare diseases. Positive results can boost investor confidence and drive stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
1 month ago
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) reported Q4 and full year 2024 financial results, highlighting progress in its NGN-401 Phase 1/2 trial for Rett syndrome with positive interim efficacy data.
Why It Matters
Neurogene's positive interim data for NGN-401 in Rett syndrome may enhance investor confidence, potentially driving stock performance and attracting interest in its future prospects.
Source: Business Wire
Market Sentiment:
Neutral
Neurogene to Participate in Upcoming Conferences
2 months ago
Quick Summary
Neurogene Inc. (NASDAQ: NGNE) will participate in the TD Cowen 45th Annual Health Care Conference on March 3 at 9:50 a.m. ET, engaging in a fireside chat and investor meetings.
Why It Matters
Neurogene's participation in key healthcare conferences signals its commitment to transparency and engagement, potentially attracting investor interest and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About NGNE Stock
What is Neurogene Inc.'s (NGNE) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Neurogene Inc. (NGNE) has a median price target of $46.00. The highest price target is $72.00 and the lowest is $16.00.
Is NGNE stock a good investment in 2025?
According to current analyst ratings, NGNE has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NGNE stock?
Wall Street analysts predict NGNE stock could reach $46.00 in the next 12 months. This represents a 212.3% increase from the current price of $14.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurogene Inc.'s business model?
Neurogene Inc. operates by developing innovative gene therapies targeted at severe neurological disorders. The company generates revenue through partnerships, grants, and potential future sales of its therapies, focusing on rare conditions with significant unmet needs.
What is the highest forecasted price for NGNE Neurogene Inc.?
The highest price target for NGNE is $72.00 from Mani Foroohar at Leerink Partners, which represents a 388.8% increase from the current price of $14.73.
What is the lowest forecasted price for NGNE Neurogene Inc.?
The lowest price target for NGNE is $16.00 from Keith Tapper at BMO Capital, which represents a 8.6% increase from the current price of $14.73.
What is the overall NGNE consensus from analysts for Neurogene Inc.?
The overall analyst consensus for NGNE is bullish. Out of 6 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $46.00.
How accurate are NGNE stock price projections?
Stock price projections, including those for Neurogene Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 4:00 PM UTC